NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $30.34 +0.15 (+0.50%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$30.88 +0.54 (+1.76%) As of 07:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Stoke Therapeutics Stock (NASDAQ:STOK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Stoke Therapeutics alerts:Sign Up Key Stats Today's Range$29.95▼$31.4150-Day Range$12.96▼$30.5052-Week Range$5.35▼$32.40Volume1.02 million shsAverage Volume1.25 million shsMarket Capitalization$1.66 billionP/E Ratio35.69Dividend YieldN/APrice Target$29.00Consensus RatingModerate Buy Company Overview Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins. The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy. In addition to STK-001, Stoke is advancing STK-002, its preclinical candidate for spinocerebellar ataxia type 6 (SCA6), along with other discovery-stage programs targeting genetic diseases characterized by insufficient protein levels. Stoke’s approach aims to address the underlying genetic deficiency rather than solely treating symptoms, positioning its pipeline to potentially benefit a range of patient populations with high unmet medical needs. Since going public on the Nasdaq exchange in early 2020, Stoke Therapeutics has grown its research capabilities and established strategic collaborations to support its development efforts. The company’s leadership team brings together expertise in molecular biology, neurology and clinical development, guiding Stoke’s mission to translate its TANGO platform into transformative therapies. Stoke serves patient communities and clinical partners globally, with ongoing and planned trials conducted across North America and Europe.AI Generated. May Contain Errors. Read More Stoke Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreSTOK MarketRank™: Stoke Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 419th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Stoke Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageStoke Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Stoke Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is 35.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 231.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is 35.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 84.98.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 7.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.78% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 6.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.59 Percentage of Shares Shorted20.78% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 6.05%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.38 News SentimentStoke Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Stoke Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 18 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows4 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,129,406.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Stoke Therapeutics is held by insiders.Read more about Stoke Therapeutics' insider trading history. Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STOK Stock News HeadlinesStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $250,700.00 in StockOctober 8, 2025 | insidertrades.comStoke Therapeutics Earns Composite Rating UpgradeOctober 13 at 11:03 AM | msn.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.October 14 at 2:00 AM | Paradigm Press (Ad)Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00October 13 at 2:27 AM | americanbankingnews.comNeedham Maintains Stoke Therapeutics (STOK) Buy RecommendationOctober 10, 2025 | msn.comWhat 4 Analyst Ratings Have To Say About Stoke TherapeuticsOctober 10, 2025 | benzinga.comStoke Therapeutics price target raised to $35 from $22 at NeedhamOctober 10, 2025 | msn.comBiogen, Stoke Therapeutics present follow-up analyses from zorevunersen studiesOctober 10, 2025 | msn.comSee More Headlines STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $11.03 at the beginning of the year. Since then, STOK stock has increased by 175.1% and is now trading at $30.34. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its earnings results on Tuesday, August, 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a trailing twelve-month return on equity of 18.32% and a net margin of 26.25%. Read the conference call transcript. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (1.64%). Insiders that own company stock include Skorpios Trust, Edward M Md Kaye, Stephen J Tulipano, Barry Ticho and Jonathan Allan. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings8/12/2025Today10/14/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STOK CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year Founded2014Price Target and Rating Average Price Target for Stoke Therapeutics$29.00 High Price Target$35.00 Low Price Target$22.00 Potential Upside/Downside-4.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.85 Trailing P/E Ratio35.69 Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.98 million Net Margins26.25% Pretax Margin26.90% Return on Equity18.32% Return on Assets15.48% Debt Debt-to-Equity RatioN/A Current Ratio6.98 Quick Ratio6.98 Sales & Book Value Annual Sales$36.56 million Price / Sales45.48 Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book7.02Miscellaneous Outstanding Shares54,800,000Free Float49,591,000Market Cap$1.66 billion OptionableOptionable Beta1.24 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:STOK) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.